Keywords: positive, data, palatin, king, pt-141, firms, technologies
Positive data for Palatin and King's PT-141
Article | 14 February 2005
US firms Palatin Technologies and King Pharmaceuticals have reported encouraging results from a Phase IIa double-blind, randomized, placebo-controlled, single-dose, cross-over ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
